Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab PK in Healthy Chinese Adults
NCT03329209Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vedolizumab in ulcerative colitis (UC) and Crohn's disease, sponsored by Takeda. Primary endpoints: Maximum Observed Serum Concentration, Area Under the Serum Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Mar 2018; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03329209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329209.